Hansoh Pharma Reports Positive Interim Phase 3 Results for Risvutatug Rezetecan in Relapsed Small Cell Lung Cancer

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-13
Category: health
Source: Hansoh Pharmaceutical Group Co., Ltd.

Hansoh Pharma announced positive interim results from the Phase 3 ARTEMIS-008 study of Risvutatug Rezetecan (HS-20093) in patients with relapsed small cell lung cancer. This marks a significant milestone for the B7-H3-directed antibody-drug conjugate, moving it towards regulatory submission in China.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai